Abstract
Various drug combinations are used in the treatment of COPD. Most experiences have been gained with ICS and LABA administered twice daily.
The article provides information on the effectiveness of the inhaled corticosteroid fluticasone furoate and the ultra-long-acting beta-2 agonist vilanterol trifenatate. A novel fixed combination of the two drugs called Relvar Ellipta will be available soon.
Its effectiveness and rapid onset of action has been proven in patients with both COPD and bronchial asthma. In both groups, results of many studies have shown improved lung function, fewer exacerbations, a better qualify of life and an acceptable spectrum of adverse effects.
The main benefit of the new drug combination is that it offers 24-hour efficacy from a once-daily dose.